Idiopathic thrombocytopenic purpura News and Research

RSS
Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Novel therapeutic approaches for various forms of thrombocytopenia

Novel therapeutic approaches for various forms of thrombocytopenia

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

FDA approves GSK's Promacta (Eltrombopag)

FDA approves GSK's Promacta (Eltrombopag)

Men get autoimmune diseases, too!

Men get autoimmune diseases, too!

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

Costly IVIg could be replaced with synthetic blood product

Costly IVIg could be replaced with synthetic blood product

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.